Risk factors
Mirum Pharmaceuticals (MIRM) risk factors
Item 1A of every Mirum Pharmaceuticals, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors73 risks8 new5 dropped19 reworded
Mirum added eight new risks addressing clinical trials of brelovitug, LIVMARLI generic competition under Hatch-Waxman, and international data privacy and tax changes.
Filed Feb 25, 2026 - FY2024 10-K risk factors70 risks
Mirum relies heavily on commercializing its approved medicines and rare disease pipeline globally. Operations depend on third-party manufacturers, contractors, and licensing agreements. Financial success requires navigating complex pricing, reimbursement, and intense biopharmaceutical competition.
Filed Feb 26, 2025